Animal health firm Zoetis Inc. (NYSE: ZTS) reported Q2 2025 adjusted EPS of $1.76, up from $1.56 last year, beating consensus. Sales were $2.50 billion, up 4% YoY, exceeding the consensus. U.S. segment revenue was $1.4 billion, up 4% and 7% organically.

Companion animal product sales rose 9%, driven by Simparica Trio and key dermatology products. Livestock product sales declined 21% due to divestiture, but organically decreased 2% due to product supply timing and competition.

Zoetis raised its fiscal 2025 revenue guidance to $9.45 billion-$9.6 billion and adjusted EPS to $6.30-$6.40. Adjusted net income is expected to be $2.825 billion-$2.875 billion. Guidance reflects foreign exchange rates and tariffs impact.

Despite concerns around Librela, Zoetis’s performance remains strong with raised guidance. Shares initially rose post-earnings but have since retraced. Analysts note potential challenges but are optimistic about future growth within Zoetis’s portfolio. Stock is currently trading lower at $147.84.

Read more at Yahoo Finance: Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline